OBJECTIVES The purpose of this study was to determine whether bleeding risk varies depending on which P2Y 12 receptor inhibitor agent is used.
METHODS
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Outcomes of AMI Patients
DATA COLLECTION AND STUDY ENDPOINTS. Baseline clinical characteristics, demographics, past medical history, in-hospital antiplatelet therapy or antithrombotic therapy use, laboratory studies, PCI data, and discharge medications were abstracted from the medical record or patient interviews into the TRANSLATE-ACS data collection form using standardized data elements and definitions (10) . Data were screened upon entry, and only those meeting pre-determined criteria for completeness and accuracy were entered into the database for analysis.
Post-discharge study follow-up was conducted via centralized telephone interviews by trained was used in 526 patients, whereas triple therapy with prasugrel (triple-P) was used in 91 (4.5% and 0.8% of the overall study population, respectively). Among patients discharged on triple therapy, warfarin was the predominant oral anticoagulant used in 572 patients (93%), whereas novel oral anticoagulants (dabigatran or rivaroxaban) were used in 45 patients.
Among patients discharged on DAPT alone, 7, 715 (66% of the overall study population) were treated with clopidogrel (dual-C) and 3,424 (29%) received prasugrel (dual-P).
Prior to admission, 347 (3%) patients were on home oral anticoagulant therapy. The indications for anticoagulation were: prosthetic valve (n ¼ 26, 7%), venous thromboembolism (n ¼ 69, 20%), atrial fibrillation/atrial flutter (n ¼ 200, 58%), other (n ¼ 48, 14%), and missing (n ¼ 4, 1%). Among patients on home anticoagulant therapy prior to admission, 215 (62%) were discharged on triple-C, 16 (5%) were discharged on triple-P, 104 (30%) were discharged on dual-C, and 12 (3%) were discharged on dual-P.
Overall, 231 of the 617 (37%) patients were discharged on triple therapy, and 116 of the 11,139 (1.0%) patients discharged on DAPT only were taking an oral anticoagulant prior to admission.
Baseline characteristics of the study cohort are shown according to discharge treatment group in Table 1 . Dual-C patients were younger than those treated with triple-C; however, there was minimal age difference between dual-and triple-P patients. Similar to the overall results from the TRANSLATE-ACS study (13) , patients treated with prasugrel were younger and were more likely to be male than those treated with clopidogrel, regardless of oral anticoagulant use.
In general, patients treated with triple therapy had a higher prevalence of cardiovascular comorbidities such as prior MI, revascularization, and heart failure, and were more likely to present with cardiogenic shock or heart failure compared with patients treated with DAPT, irrespective of the P2Y 12 receptor inhibitor used. Rates of STEMI presentation and drug-eluting stent use were higher among patients treated Values are median (interquartile range) or n (%).
BP ¼ blood pressure; CABG ¼ coronary artery bypass graft surgery; dual-C ¼ dual antiplatelet therapy with clopidogrel; dual-P ¼ dual antiplatelet therapy with prasugrel; GI/GU ¼ gastrointestinal/ genitourinary; HF ¼ heart failure; MI ¼ myocardial infarction; PAD ¼ peripheral artery disease; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction; TIA ¼ transient ischemic attack; triple-C ¼ triple therapy with clopidogrel; triple-P ¼ triple therapy with prasugrel. Values are n (%) unless otherwise indicated. *All comparisons designate the second treatment group as the reference group. †Adjusted results based on inverse probability weighted propensity adjustment.
BARC ¼ Bleeding Academic Research Consortium; CI ¼ confidence interval; IRR ¼ incident rate ratio; other abbreviations as in Table 1 .
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with prasugrel regardless of oral anticoagulant use.
Drug-eluting stents were used in 59% of patients discharged on triple-C and 74% among patients discharged on triple-P. Notably, an aspirin dose >81 mg was prescribed in approximately one-third of patients discharged on triple therapy (44% among prasugreltreated and 34% among clopidogrel-treated patients) and approximately two-thirds of patients discharged on dual therapy. Overall, >4% of patients were lost to follow-up at 6 months and >5% at 12 months for each discharge group.
ANY BARC-DEFINED BLEEDING. At 6 months postdischarge, triple-C was associated with a significantly higher risk of any BARC-defined bleeding compared with dual-C after multivariable analysis PATIENT-REPORTED-ONLY BLEEDING. Bleeding events were stratified into those that involved rehospitalization and those that were patient-reported only.
As shown in Values are n (%) unless otherwise indicated. *All comparisons designate the second treatment group as the reference group. †Adjusted results based on inverse probability weighted propensity adjustment.
OR ¼ odds ratio; other abbreviations as in Tables 1 and 2 . Values are n (%) unless otherwise specified. *All comparisons designate the second treatment group as the reference group. †Adjusted results based on inverse probability weighted propensity adjustment.
Abbreviations as in Tables 1 and 2 .
Overall rates of GUSTO moderate/severe bleeding within 6 months after acute MI were low. Among Relative to aspirin alone, the HR was 1.22 for aspirin þ clopidogrel, 1.46 for aspirin þ warfarin, and 1.65
for aspirin þ clopidogrel þ warfarin (19) .
Prasugrel is a higher-potency P2Y 12 Values are n (%). *All comparisons designate the second treatment group as the reference group. †Adjusted results based on inverse probability weighted propensity adjustment.
HR ¼ hazard ratio; MACE ¼ major adverse cardiac events; all other abbreviations as in Tables 1 and 2 . Abbreviations as in Tables 1 and 5 .
Jackson et al.
Outcomes of AMI Patients receptor inhibitor was assigned in a randomized manner. Therefore, despite rigorous multivariable adjustment, residual selection bias and unmeasured confounding likely remains. Second, although this is the largest cohort described so far, the number of patients that received triple-P was very low. Finally, the small number of patients discharged on prasugrel limits our ability to adjust for potential confounding and attenuates the strength of the derived conclusions.
CONCLUSIONS
In this observational study of contemporary MI patients treated with PCI and either clopidogrel or prasugrel, we observed a significantly higher risk of bleeding when an oral anticoagulant was added to DAPT. Triple therapy with prasugrel was prescribed to a select group of patients and was associated with a higher risk of any BARC bleeding compared with triple therapy with clopidogrel; however, this increase in risk was primarily observed for patient-reported bleeding that did not require rehospitalization. In contrast, we observed no significant difference in the risk of rehospitalized bleeding between triple-P and -C groups.
Data from larger studies are needed to determine the overall benefit of different P2Y 12 WHAT IS NEW? We found that among MI patients, the addition of an oral anticoagulant was associated with a significantly greater risk of any BARC-defined bleeding relative to DAPT, regardless of which P2Y 12 receptor inhibitor was selected. Among patients on triple therapy, prasugrel use was associated with higher patientreported-only bleeding, but not bleeding requiring rehospitalization, than clopidogrel-treated patients.
WHAT IS NEXT? Data from larger studies are needed to determine the overall benefit of different P2Y 12 receptor inhibitor regimens in patients requiring both systemic anticoagulation and DAPT after a recent MI and/or PCI.
